ライフサイエンスコーパス: mesalamine

1 secondary analyses indicated the efficacy of mesalamine.

2 t a novel antineoplastic molecular effect of mesalamine.

3 erative effects of TNF-alpha were blocked by mesalamine.

4 degradation of Ikappa-Balpha were blocked by mesalamine.

5 r, or ceramide in the presence or absence of mesalamine.

6 assess the noninferiority of delayed-release mesalamine 1.6-2.4 g/day administered once daily compare

7 Patients received mesalamine (1.2 g, 2.4 g, or 4.8 g) or placebo once dail

8 greater proportion of patients receiving MMX mesalamine 2.4 g/day given once daily (40.5%; P = .01) a

9 -to-moderate ulcerative colitis received MMX mesalamine 2.4 g/day or 4.8 g/day given once daily, ASAC

10 at were given budesonide MMX (9 mg or 6 mg), mesalamine (2.4 g, as reference), or placebo for 8 weeks

11 vs standard (2-3 g/d) vs high-dose (>3 g/d) mesalamine); (2) comparison of different dosing regimens

12 Short-term treatment with oral mesalamine (3 g once daily) appears to be ineffective.

13 omized 131 patients to receive 6-MP (50 mg), mesalamine (3 g), or placebo daily in a double-blind, do

14 Delayed-release mesalamine 4.8 g/day (800-mg tablet) is efficacious and

15 assess the noninferiority of delayed-release mesalamine 4.8 g/day (Asacol HD, 800-mg tablet; Procter

16 cted to determine the efficacy and safety of mesalamine 4.8 g/day compared with 2.4 g/day for the tre

17 Although mesalamine 4.8 g/day was not statistically different fro

18 rectal cancer, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and fola

19 The aim of this study was to investigate mesalamine, a standard therapy for inflammatory bowel di

20 tion, 43% of patients who received 4.8 g/day mesalamine achieved clinical remission at week 6 compare

21 placebo (P = .0006); 44.0% of patients given mesalamine achieved clinical remission, but budesonide w

22 f 389) of patients who received 4.8 g/day of mesalamine achieved treatment success at week 6, compare

23 No new adverse events were identified with mesalamine administration.

24 Although a protective role for mesalamine against colon cancer in ulcerative colitis ha

25 cell and biofilm formation, suggesting that mesalamine aids in diminishing the capacity of bacteria

26 In this report, we demonstrate that mesalamine, an anti-inflammatory aminosalicylate, dose-d

27 s achieved by 30.0% of patients treated with mesalamine and 20.6% of those given placebo, a differenc

28 luorescent dyes and commercial drugs such as mesalamine and doxorubicin, which eluted from the grippe

29 remission rates were 29.0% and 13.8% in the mesalamine and placebo groups, respectively (difference

30 The Mesalamine and Reproductive Health Study (MARS) was desi

31 In contrast, both mesalamine and sodium salicylate have been shown to lowe

32 s take drugs to reduce inflammation (such as mesalamine and steroids).

33 IEC-18 cells were treated with 0.3-3 mmol/L mesalamine and thermally stressed (39 degrees C-42 degre

34 mmunomodulator therapy only after failure of mesalamine), and the role of corticosteroids and mesalam

35 95% CI, 61%-91%) in patients receiving 6-MP, mesalamine, and placebo, respectively.

36 zine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, and corticosteroids, including budesonide)

37 rolled trials that compared the abilities of mesalamine, antibiotics, budesonide, immunomodulators, a

38 Although mesalamines are still often used to treat Crohn disease,

39 multicenter study to evaluate budesonide and mesalamine as short-term treatments for collagenous coli

40 fety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-d

41 at evaluated the efficacy of delayed-release mesalamine (Asacol 800-mg tablet) 4.8 g/day.

42 A delayed-release oral mesalamine (ASACOL; Procter & Gamble, Cincinnati, OH) re

43 Once-daily dosing of delayed-release mesalamine at doses of 1.6-2.4 g/day was shown to be as

44 Mesalamine augments thermal induction of the intestinal

45 colitis, the platform carrying budesonide or mesalamine becomes more viscoelastic near body temperatu

46 in nonepithelial cells, the possibility that mesalamine confers cell protection by increasing intesti

47 e results are consistent with the model that mesalamine contributes to chemoprevention in CAC by redu

48 Among patients treated with mesalamine delayed/extended-release tablets (Mezavant(R)

49 s in patients using maintenance therapy with mesalamine derivatives has been expanded.

50 Mesalamine did not reduce the rate of diverticulitis rec

51 Mesalamine did not reduce time to recurrence, and the pr

52 in human intestinal epithelial cells and if mesalamine directly interacts with PN or its precursor,

53 The efficacy of mesalamine does not appear to be strong data supported.

54 at 65 years was longest for patients taking mesalamine (females: 22.1 years, 95% CI 21.8-22.5; males

55 lamine), and the role of corticosteroids and mesalamine for induction and/or maintenance of remission

56 budesonide once daily, Budenofalk, n = 30), mesalamine granules (3 g mesalamine once daily, Salofalk

57 Although mesalamine had no effects on the basal hsp72 expression

58 Mesalamine has been proposed as a treatment option for c

59 Mesalamine has many effects and is commonly used for the

60 Mesalamine has shown efficacy in preventing relapse in i

61 We investigated the efficacy of mesalamine in preventing recurrence of diverticulitis in

62 The beneficial effects of mesalamine in the treatment of inflammatory bowel diseas

63 The practice of dosing mesalamines in divided doses for the treatment of ulcera

64 g Crohn's disease (e.g., corticosteroids and mesalamine); in fact, some medications are believed to b

65 Mesalamine inhibits TNF-alpha-mediated effects on intest

66 Mesalamine is a mainstay therapeutic agent in chronic ul

67 the role of anti-inflammatory treatment with mesalamine is being actively investigated.

68 Mesalamine is not recommended for this indication.

69 It is not clear what induction dose of mesalamine is optimal for treating patients with mildly

70 es (sulfalsalazine vs diazo-bonded 5-ASAs vs mesalamine; low- (<2 g) vs standard (2-3 g/d) vs high-do

71 as beneficial as previously thought and that mesalamine might be useful.

72 Furthermore, a new 5-aminosalicylic acid (mesalamine MMX) has been released that effectively induc

73 MMX mesalamine offers effective and convenient mesalamine th

74 The effects of mesalamine on basal expression and the threshold and tim

75 Effects of mesalamine on epithelial proliferation and activation of

76 exerts a synergistic therapeutic effect with mesalamine on mouse colitis.

77 Effects of mesalamine on P-beta-catenin staining and function were

78 The effects of mesalamine on PN decomposition and NO half-life were det

79 f chemoprevention, we examined the effect of mesalamine on TC22 expression using LS180 colon cancer c

80 bowel disease, we investigated the effect of mesalamine on TNF-alpha-regulated signal transduction an

81 udenofalk, n = 30), mesalamine granules (3 g mesalamine once daily, Salofalk, n = 25), or placebo for

82 Mesalamine or sulfasalazine (2 mM), but not sulfapyridin

83 of ulcerative colitis, starting with topical mesalamine or topical corticosteroids.

84 isits (OR, 2.0; 95% CI: 1.4-3.0), and use of mesalamine (OR, 2.8; 95% CI: 1.7-4.4).

85 al remission, but budesonide was superior to mesalamine (P = .0035).

86 Mesalamine protected the epithelial barrier function of

87 Mesalamine rapidly degraded PN, whereas the half-life of

88 reviously treated with corticosteroids, oral mesalamines, rectal therapies, or multiple UC medication

89 -10(-/-) and human colitis samples show that mesalamine reduced Akt activation and P-beta-catenin lev

90 In IL-10(-/-) mice, mesalamine reduced CID concordant with inhibition of cry

91 mens with severe inflammation suggested that mesalamine reduced P-beta-catenin levels in tissue refra

92 present study addressed the possibility that mesalamine reduces beta-catenin-associated progenitor ce

93 etwork meta-analysis, compared with placebo, mesalamine (relative risk [RR], 0.60; 95% credible inter

94 Derivatives of 5-aminosalicylic acid (mesalamine) represent a mainstay in inflammatory bowel d

95 Mesalamine resulted in a dose-dependent decrease in PN-i

96 (RR, 0.01; 95% CrI, 0.00-0.05), but neither mesalamine (RR, 0.67; 95% CrI, 0.39-1.08) nor budesonide

97 -beta-catenin levels in tissue refractory to mesalamine's anti-inflammatory effects.

98 Mesalamine serves as the gold standard in treating ulcer

99 ; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under

100 reover, treatment with 5-ASAs (sulfasalazine/mesalamine) shows a high association with COVID-19/IBD m

101 We conclude that mesalamine, sulfasalazine, and rosiglitazone significant

102 , biologic monotherapy, combination therapy, mesalamine, systemic steroids, and no therapy.

103 X mesalamine offers effective and convenient mesalamine therapy, potentially improving treatment comp

104 IBD medication exposures included mesalamine, thiopurines, anti-tumor necrosis factor biol

105 , patients were required to initiate an oral mesalamine treatment between January 2005 and December 2

106 Here, we show that mesalamine treatment rapidly decreases polyphosphate lev

107 tis (UC), little is known about adherence to mesalamine treatments and determinants that can predict

108 y was to assess adherence and persistence to mesalamine treatments and their potential determinants i

109 C exhibited low adherence and persistence to mesalamine treatments.

110 itively associated with HRU, while NSAID and mesalamine use were inversely associated on bivariate an

111 A sample of 1,681 of the new oral mesalamine users (mean age = 55.3) patients was obtained

112 lysis was conducted using a random sample of mesalamine users with UC.

113 high-strength (1.2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) tech

114 uble-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ulcera

115 uated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent div

116 T29 cells were divided in several protocols: mesalamine was administered 2 hours before, simultaneous

117 nt decrease in PN-induced apoptosis, whether mesalamine was administered before (>10 micromol/L; IC50

118 Once-daily MMX mesalamine was efficacious and well-tolerated for the in

119 Mesalamine was found to inhibit IL-1-stimulated RelA pho

120 Mesalamine was not superior to placebo in preventing rec

121 ubjects given 9 mg or 6 mg budesonide MMX or mesalamine were 17.9%, 13.2%, and 12.1%, respectively, c

122 ubjects given 9 mg or 6 mg budesonide MMX or mesalamine were 28.5%, 28.9%, and 25.0%, respectively, c

123 atients given 9 mg or 6 mg budesonide MMX or mesalamine were 33.3%, 30.6%, and 33.9%, respectively, c

124 ubjects given 9 mg or 6 mg budesonide MMX or mesalamine were 41.5%, 35.5%, and 33.1%, respectively, c

125 e activation of MAP kinase were inhibited by mesalamine, whereas epidermal growth factor activation o

126 with the FDA-approved anti-inflammatory drug mesalamine, which has recently been shown to attenuate p

127 l was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical,